No price history available.
Key financial summary
Financials in IDR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | IDRm | 22,545,419 | 25,673,757 | 28,027,488 | 28,507,873 | 30,957,341 | 32,960,723 | N/A | N/A |
| Operating profit | IDRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | IDRm | 680,598 | 847,881 | 847,533 | 688,499 | 741,774 | 789,194 | N/A | N/A |
| EPS reported | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | IDRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | IDRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | IDRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in IDR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
PT Enseval Putera Megatrading Tbk., together with its associated companies, plays a significant role in Indonesia's pharmaceutical sector, primarily through the distribution and supply of its products. The organization's business activities are structured into three principal categories: Pharmaceutical, Consumer Products, and a diversified "Others" segment. Beyond pharmaceuticals, the company is involved in the commerce of medical and laboratory instruments and associated supplies, operates healthcare clinics, provides dental and various other specialized equipment, and offers calibration services. Furthermore, its trading ventures extend to raw materials crucial for pharmaceutical production, consumable goods for hemodialysis treatment, and a range of food and beverage items. The firm also delivers comprehensive warehousing solutions, including climate-controlled environments like chiller, cool, and ambient rooms, in addition to container chiller options. Founded in 1973, the company was originally named PT Arya Gupta Cempaka, adopting its current designation, PT Enseval Putera Megatrading Tbk., in August 1993. Headquartered in East Jakarta, Indonesia, it functions as a subsidiary of PT Kalbe Farma Tbk.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
PT Enseval Putera Megatrading Tbk. (EPMT.JK)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
PT Enseval Putera Megatrading Tbk., together with its associated companies, plays a significant role in Indonesia's pharmaceutical sector, primarily through the distribution and supply of its products. The organization's business activities are structured into three principal categories: Pharmaceutical, Consumer Products, and a diversified "Others" segment. Beyond pharmaceuticals, the company is involved in the commerce of medical and laboratory instruments and associated supplies, operates healthcare clinics, provides dental and various other specialized equipment, and offers calibration services. Furthermore, its trading ventures extend to raw materials crucial for pharmaceutical production, consumable goods for hemodialysis treatment, and a range of food and beverage items. The firm also delivers comprehensive warehousing solutions, including climate-controlled environments like chiller, cool, and ambient rooms, in addition to container chiller options. Founded in 1973, the company was originally named PT Arya Gupta Cempaka, adopting its current designation, PT Enseval Putera Megatrading Tbk., in August 1993. Headquartered in East Jakarta, Indonesia, it functions as a subsidiary of PT Kalbe Farma Tbk.